Loading…

Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"

Persistence of infection despite extensive chemotherapy with antibiotics displaying low MICs is a hallmark of lung disease caused by (Mab). Thus, the classical MIC assay is a poor predictor of clinical outcome. Discovery of more efficacious antibiotics requires more predictive potency assays. As a m...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in microbiology 2020-03, Vol.11, p.359-359
Main Authors: Yam, Yee-Kuen, Alvarez, Nadine, Go, Mei-Lin, Dick, Thomas
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643
cites cdi_FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643
container_end_page 359
container_issue
container_start_page 359
container_title Frontiers in microbiology
container_volume 11
creator Yam, Yee-Kuen
Alvarez, Nadine
Go, Mei-Lin
Dick, Thomas
description Persistence of infection despite extensive chemotherapy with antibiotics displaying low MICs is a hallmark of lung disease caused by (Mab). Thus, the classical MIC assay is a poor predictor of clinical outcome. Discovery of more efficacious antibiotics requires more predictive potency assays. As a mycobacterium, Mab is an obligate aerobe and a chemo-organo-heterotroph - it requires oxygen and organic carbon sources for growth. However, bacteria growing in patients can encounter micro-environmental conditions that are different from aerated nutrient-rich broth used to grow planktonic cultures for MIC assays. These conditions may include oxygen and nutrient limitation which should arrest growth. Furthermore, Mab was shown to grow as biofilms . Here, we show Mab Bamboo, a clinical isolate we use for Mab drug discovery, can survive oxygen deprivation and nutrient starvation for extended periods of time in non-replicating states and developed an model where the bacterium grows as biofilm. Using these culture models, we show that non-replicating or biofilm-growing bacteria display tolerance to clinically used anti-Mab antibiotics, consistent with the observed persistence of infection in patients. To demonstrate the utility of the developed "persister" assays for drug discovery, we determined the effect of novel agents targeting membrane functions against these physiological forms of the bacterium and find that these compounds show "anti-persister" activity. In conclusion, we developed "persister" assays to fill an assay gap in Mab drug discovery compound progression and to enable identification of novel lead compounds showing "anti-persister" activity.
doi_str_mv 10.3389/fmicb.2020.00359
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ec78e81d4a1e46769b82abb3867c231e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ec78e81d4a1e46769b82abb3867c231e</doaj_id><sourcerecordid>2381620456</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643</originalsourceid><addsrcrecordid>eNpVkUtPAyEURonRqNHuXZmJKzetvIaBjYnx2aRGF5q4I0AvdZqZojBj9N-LrZqWDeTy3cMNB6EjgkeMSXXm29rZEcUUjzBmpdpC-0QIPmSYvmyvnffQIKU5zovnLMa7aI9RonjJqn10fv3ZRWihuIr9rHgKDUSzcFAEX9x_uWCN6yDWfVsYmxyk1Kfi5BFiqlOup5NDtONNk2Dwux-g55vrp8u74eThdnx5MRk6Lmg3rKakFIJxopgEo9TUAYiKSFHaEqgDTKU3znumSkGAcmu9dUoBUZ5XIDg7QOMVdxrMXL_FujXxSwdT62UhxJk2satdAxpcJUGSKTcEuKiEspIaa5kUlaOMQGadr1hvvW0hj7Loomk2oJs3i_pVz8KHrrDgnMkMOP0FxPDeQ-p0W-fPaRqzgNAnTZkkgmJeihzFq6iLIaUI_v8ZgvWPRb20qH8s6qXF3HK8Pt5_w58z9g1zC5mK</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2381620456</pqid></control><display><type>article</type><title>Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"</title><source>PubMed Central</source><creator>Yam, Yee-Kuen ; Alvarez, Nadine ; Go, Mei-Lin ; Dick, Thomas</creator><creatorcontrib>Yam, Yee-Kuen ; Alvarez, Nadine ; Go, Mei-Lin ; Dick, Thomas</creatorcontrib><description>Persistence of infection despite extensive chemotherapy with antibiotics displaying low MICs is a hallmark of lung disease caused by (Mab). Thus, the classical MIC assay is a poor predictor of clinical outcome. Discovery of more efficacious antibiotics requires more predictive potency assays. As a mycobacterium, Mab is an obligate aerobe and a chemo-organo-heterotroph - it requires oxygen and organic carbon sources for growth. However, bacteria growing in patients can encounter micro-environmental conditions that are different from aerated nutrient-rich broth used to grow planktonic cultures for MIC assays. These conditions may include oxygen and nutrient limitation which should arrest growth. Furthermore, Mab was shown to grow as biofilms . Here, we show Mab Bamboo, a clinical isolate we use for Mab drug discovery, can survive oxygen deprivation and nutrient starvation for extended periods of time in non-replicating states and developed an model where the bacterium grows as biofilm. Using these culture models, we show that non-replicating or biofilm-growing bacteria display tolerance to clinically used anti-Mab antibiotics, consistent with the observed persistence of infection in patients. To demonstrate the utility of the developed "persister" assays for drug discovery, we determined the effect of novel agents targeting membrane functions against these physiological forms of the bacterium and find that these compounds show "anti-persister" activity. In conclusion, we developed "persister" assays to fill an assay gap in Mab drug discovery compound progression and to enable identification of novel lead compounds showing "anti-persister" activity.</description><identifier>ISSN: 1664-302X</identifier><identifier>EISSN: 1664-302X</identifier><identifier>DOI: 10.3389/fmicb.2020.00359</identifier><identifier>PMID: 32194537</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>biofilm ; drug tolerance ; Microbiology ; NTM ; nutrient starvation ; oxygen starvation</subject><ispartof>Frontiers in microbiology, 2020-03, Vol.11, p.359-359</ispartof><rights>Copyright © 2020 Yam, Alvarez, Go and Dick.</rights><rights>Copyright © 2020 Yam, Alvarez, Go and Dick. 2020 Yam, Alvarez, Go and Dick</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643</citedby><cites>FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064438/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064438/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32194537$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yam, Yee-Kuen</creatorcontrib><creatorcontrib>Alvarez, Nadine</creatorcontrib><creatorcontrib>Go, Mei-Lin</creatorcontrib><creatorcontrib>Dick, Thomas</creatorcontrib><title>Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"</title><title>Frontiers in microbiology</title><addtitle>Front Microbiol</addtitle><description>Persistence of infection despite extensive chemotherapy with antibiotics displaying low MICs is a hallmark of lung disease caused by (Mab). Thus, the classical MIC assay is a poor predictor of clinical outcome. Discovery of more efficacious antibiotics requires more predictive potency assays. As a mycobacterium, Mab is an obligate aerobe and a chemo-organo-heterotroph - it requires oxygen and organic carbon sources for growth. However, bacteria growing in patients can encounter micro-environmental conditions that are different from aerated nutrient-rich broth used to grow planktonic cultures for MIC assays. These conditions may include oxygen and nutrient limitation which should arrest growth. Furthermore, Mab was shown to grow as biofilms . Here, we show Mab Bamboo, a clinical isolate we use for Mab drug discovery, can survive oxygen deprivation and nutrient starvation for extended periods of time in non-replicating states and developed an model where the bacterium grows as biofilm. Using these culture models, we show that non-replicating or biofilm-growing bacteria display tolerance to clinically used anti-Mab antibiotics, consistent with the observed persistence of infection in patients. To demonstrate the utility of the developed "persister" assays for drug discovery, we determined the effect of novel agents targeting membrane functions against these physiological forms of the bacterium and find that these compounds show "anti-persister" activity. In conclusion, we developed "persister" assays to fill an assay gap in Mab drug discovery compound progression and to enable identification of novel lead compounds showing "anti-persister" activity.</description><subject>biofilm</subject><subject>drug tolerance</subject><subject>Microbiology</subject><subject>NTM</subject><subject>nutrient starvation</subject><subject>oxygen starvation</subject><issn>1664-302X</issn><issn>1664-302X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtPAyEURonRqNHuXZmJKzetvIaBjYnx2aRGF5q4I0AvdZqZojBj9N-LrZqWDeTy3cMNB6EjgkeMSXXm29rZEcUUjzBmpdpC-0QIPmSYvmyvnffQIKU5zovnLMa7aI9RonjJqn10fv3ZRWihuIr9rHgKDUSzcFAEX9x_uWCN6yDWfVsYmxyk1Kfi5BFiqlOup5NDtONNk2Dwux-g55vrp8u74eThdnx5MRk6Lmg3rKakFIJxopgEo9TUAYiKSFHaEqgDTKU3znumSkGAcmu9dUoBUZ5XIDg7QOMVdxrMXL_FujXxSwdT62UhxJk2satdAxpcJUGSKTcEuKiEspIaa5kUlaOMQGadr1hvvW0hj7Loomk2oJs3i_pVz8KHrrDgnMkMOP0FxPDeQ-p0W-fPaRqzgNAnTZkkgmJeihzFq6iLIaUI_v8ZgvWPRb20qH8s6qXF3HK8Pt5_w58z9g1zC5mK</recordid><startdate>20200304</startdate><enddate>20200304</enddate><creator>Yam, Yee-Kuen</creator><creator>Alvarez, Nadine</creator><creator>Go, Mei-Lin</creator><creator>Dick, Thomas</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200304</creationdate><title>Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"</title><author>Yam, Yee-Kuen ; Alvarez, Nadine ; Go, Mei-Lin ; Dick, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>biofilm</topic><topic>drug tolerance</topic><topic>Microbiology</topic><topic>NTM</topic><topic>nutrient starvation</topic><topic>oxygen starvation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yam, Yee-Kuen</creatorcontrib><creatorcontrib>Alvarez, Nadine</creatorcontrib><creatorcontrib>Go, Mei-Lin</creatorcontrib><creatorcontrib>Dick, Thomas</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yam, Yee-Kuen</au><au>Alvarez, Nadine</au><au>Go, Mei-Lin</au><au>Dick, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"</atitle><jtitle>Frontiers in microbiology</jtitle><addtitle>Front Microbiol</addtitle><date>2020-03-04</date><risdate>2020</risdate><volume>11</volume><spage>359</spage><epage>359</epage><pages>359-359</pages><issn>1664-302X</issn><eissn>1664-302X</eissn><abstract>Persistence of infection despite extensive chemotherapy with antibiotics displaying low MICs is a hallmark of lung disease caused by (Mab). Thus, the classical MIC assay is a poor predictor of clinical outcome. Discovery of more efficacious antibiotics requires more predictive potency assays. As a mycobacterium, Mab is an obligate aerobe and a chemo-organo-heterotroph - it requires oxygen and organic carbon sources for growth. However, bacteria growing in patients can encounter micro-environmental conditions that are different from aerated nutrient-rich broth used to grow planktonic cultures for MIC assays. These conditions may include oxygen and nutrient limitation which should arrest growth. Furthermore, Mab was shown to grow as biofilms . Here, we show Mab Bamboo, a clinical isolate we use for Mab drug discovery, can survive oxygen deprivation and nutrient starvation for extended periods of time in non-replicating states and developed an model where the bacterium grows as biofilm. Using these culture models, we show that non-replicating or biofilm-growing bacteria display tolerance to clinically used anti-Mab antibiotics, consistent with the observed persistence of infection in patients. To demonstrate the utility of the developed "persister" assays for drug discovery, we determined the effect of novel agents targeting membrane functions against these physiological forms of the bacterium and find that these compounds show "anti-persister" activity. In conclusion, we developed "persister" assays to fill an assay gap in Mab drug discovery compound progression and to enable identification of novel lead compounds showing "anti-persister" activity.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>32194537</pmid><doi>10.3389/fmicb.2020.00359</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-302X
ispartof Frontiers in microbiology, 2020-03, Vol.11, p.359-359
issn 1664-302X
1664-302X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ec78e81d4a1e46769b82abb3867c231e
source PubMed Central
subjects biofilm
drug tolerance
Microbiology
NTM
nutrient starvation
oxygen starvation
title Extreme Drug Tolerance of Mycobacterium abscessus "Persisters"
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A24%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extreme%20Drug%20Tolerance%20of%20Mycobacterium%20abscessus%20%22Persisters%22&rft.jtitle=Frontiers%20in%20microbiology&rft.au=Yam,%20Yee-Kuen&rft.date=2020-03-04&rft.volume=11&rft.spage=359&rft.epage=359&rft.pages=359-359&rft.issn=1664-302X&rft.eissn=1664-302X&rft_id=info:doi/10.3389/fmicb.2020.00359&rft_dat=%3Cproquest_doaj_%3E2381620456%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-7d1566341938ea99dcee671865b5e2ce028facff39561e24bbfbc99e19f47e643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2381620456&rft_id=info:pmid/32194537&rfr_iscdi=true